Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells

Leukemia

Volumn 17, Issue 7, 2003, Pages 1333-1337

  Cai, X ^a   Yu, Y ^a   Huang, Y ^b   Zhang, L ^a   Jia, P M ^a   Zhao, Q ^c   Chen, Z ^a   Tong, J H ^a   Dai, W ^c,d   Chen, G Q ^a,b,c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Arsenic; Mitotic arrest

Indexed keywords

ARSENIC TRIOXIDE; CAFFEINE; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 20; CYCLIN B1; DITHIOTHREITOL; PROTEIN KINASE; TYROSINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE POTENTIAL; METAPHASE; MITOCHONDRIAL MEMBRANE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION;

EID: 0038103842     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402983     Document Type: Article

References (26)

1. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
2. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215.
3. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 1997; 89: 376-387.
4. Kogan SC, Brown DE, Shultz DB, Truong BT, Lallemand- Breitenbach V, Guillemin MC et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PML-RARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 2001; 193: 531-543.
5. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
6. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 9: 759-767.
7. Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 1998; 12: 1866-1880.
8. 3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
9. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
10. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20: 7146-7153.
11. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
12. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772-778.
13. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999; 59: 1041-1048.
14. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. Life Sci 2002; 71: 275-285.
15. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-270.
16. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999; 249: 413-421.
17. Huang C, Li J, Ding M, Wang L, Shi X, Castranova V et al. Arsenic-induced NFkappaB transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol Cell Biochem 2001; 222: 29-34.
18. Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001; 91: 173-179.
19. Park JW, Choi YJ, Jang MA, Baek SH, Lim JH, Passaniti T. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 2001; 286: 726-734.
20. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002; 62: 529-538.
21. Gong J, Traganos F, Darzynkiewicz Z. Discrimination of G2 and mitotic cells by flow cytometry based on different expression of cyclins A and B1. Exp Cell Res 1995; 20: 226-231.
22. Kumagai A, Guo Z, Emami KH, Wang SX, Dunphy WG. The Xenopus chk1 protein kinase mediates caffeine-sensitive pathway of checkpoint control in cell-free extracts. J Cell Biol 1998; 42:1559-1569.
23. Hoyt MA. A new view of the spindle checkpoint. J Cell Biol 2001; 154: 909-911.
24. Sudakin V, Chan GK, Yen TJ. Checkpoint inhibition of the APC/C in HeLA cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 2001; 154: 925-936.
25. Morgan DO. Principal of CDK regulation. Nature 1995; 374: 131-134.
26. Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 2000; 12: 658-665.